Dr. Kshitij Domadia

Introduction

Dr Kshitij has completed his training in medical oncology from the prestigious and internationally acclaimed cancer institute- RAJIV GANDHI CANCER INSTITUTE & RESEARCH CENTRE, DELHI.

He is also a ESMO (European society of medical oncology) certified medical oncologist (ECMO).

Expertise

• Dr. Kshitij is an ESMO (European society of medical oncology) certified medical oncologist (ECMO) practising at HCG Cancer Centre, Ahmedabad.
• He is an expert in dealing with all sorts of chemotherapy, targeted therapy and immunotherapy in its most rational manner.
• His expertise in dealing with molecular aspects of oncology and precision oncology is very well acclaimed by the community.
• His expertise lies in treating cancer patients not only with the thorough academic knowledge but also with empathy, care and compassion. 
• Dr. Kshitij has a special interest in the management of breast cancers, lung cancers, head and neck cancers, genitourinary cancers

Recognition

• Dr. Kshitij has won ‘Molecular oncology grant competition’ on a research project on liquid biopsy in lung cancer at ICON Conference 2018.
• He has also secured a scholarship grant at ‘SPEAK’ BREAST CANCER conference, Mumbai in 2018.

Publications

Dr. Kshitij has many publications to his name in both reputed national and international journals. He is an invited speaker at many national conferences:

• Only 9 weeks or complete 12 months of adjuvant trastuzumab in Indian early-stage breast cancer patients: Is it the practice-changing approach in a resource-constrained setting?. Cancer Research, Statistics, and Treatment. 2020 Jul 1;3(2):401.
• Study of efficacy and tolerability of paclitaxel and carboplatin as a concurrent chemotherapeutic radiation sensitizer regimen in patients of esophageal cancer: Prospective observational study from a tertiary centre in northern India. DOI: 10.1200/JCO.2020.38.15_suppl.e16526 Journal of Clinical Oncology 38, no. 15_suppl
• Real-World Outcomes of Check Point Inhibitors Immunotherapy in Renal and Urothelial Cancers in a Tertiary Care Cancer Center in India. International Journal of Molecular & Immuno Oncology. 2019 Sep 14;4(3):63-6.
• Good response to erlotinib in a patient after progression on osimertinib: A rare case of spatiotemporal T790M heterogeneity in a patient with epidermal growth factor receptor-mutant nonsmall cell lung cancer. South Asian Journal of Cancer. 2017 Oct;6(4):179.
• Retrospective Evaluation of PD-L1 Expression in Tumour Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographical Data from a Tertiary Care Institute of Northern India. (Poster at ESMO Asia Singapore 2018)
• Clinical-Epidemiological Profile of Influenza A H1N1 Cases at a Tertiary Care Institute of Western India. Indian Journal of Applied Research, Vol.5, Issue: 10 October 2015
• Presented E-Poster at IBCC, Jaipur 2017 -“A Study of Clinico-Pathological Profile of Basal & Non-Basal Subtype of Triple Negative Breast Cancer”

Area of Interest

• LUNG CANCER
• HEAD AND NECK CANCERS
• GENITOURINARY CANCERS

Other Doctors